In reply: We thank McCallum and colleagues for their comments. In relation to their specific points:
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1 School of Medicine and Pharmacology, University of Western Australia, and Fremantle Hospital, Fremantle, WA.
- 2 Boden Institute of Obesity, Nutrition and Exercise, University of Sydney, Sydney, NSW.
Correspondence: wdavis@cyllene.uwa.edu.au
- 1. Australian Bureau of Statistics. Year book Australia, 2006. Urban and non-urban population. http://www.abs.gov.au/Ausstats/ABS@.nsf/Previousproducts/1301.0Feature%20Article72006?opendocument&tabname=Summary&prodno=1301.0 &issue=2006&num=&view= (accessed Apr 2009). (ABS Cat. No. 1301.0.)
- 2. Davis WA, Colagiuri S, Davis TME. Comparison of the Framingham and United Kingdom Prospective Diabetes Study cardiovascular risk equations in Australian patients with type 2 diabetes from the Fremantle Diabetes Study. Med J Aust 2009; 190: 180-184. <MJA full text>
- 3. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849-1861.
- 4. Simmons RK, Coleman RL, Price HC, et al. Performance of the UKPDS risk engine and the Framingham risk equations in estimating cardiovascular risk in the EPIC-Norfolk cohort. Diabetes Care 2009; 32: 708-713.
- 5. Davis WA, Knuiman MW, Davis TME. An Australian cardiovascular risk equation for type 2 diabetes: The Fremantle Diabetes Study. Int Med J 2009. Published online ahead of print: 23 Mar 2009. doi: 10.1111/j.1445-5994.2009.01958.x.
Online responses are no longer available. Please refer to our instructions for authors page for more information.